Ochre Bio
Ochre Bio is a pioneering biotech company focused on rethinking liver therapy discovery and development. They leverage an unprecedented convergence of computational and multi-omic technologies to address the complexities of liver disease. Their mission is to develop RNA therapies for major liver health challenges, aiming to transform treatment options for patients worldwide. With a foundation built on decades of expertise in genomics, machine learning, drug discovery, and development, Ochre Bio is committed to addressing unmet needs in chronic liver disease globally.
Industries
Nr. of Employees
small (1-50)
Products
Deep Phenotyping Platform
A platform that combines computational and multi-omic technologies for analyzing liver diseases.
Precision RNA Therapies
RNA-based treatments designed to reprogram livers for regeneration outside the body.
Human-Organ Perfusion Models
Proprietary models for testing therapies in live human donor livers.
RNAi Therapeutics for Liver Diseases
Developing novel RNA interference therapies targeting under-treated chronic liver diseases.
Deep Phenotyping Platform
A platform that combines computational and multi-omic technologies for analyzing liver diseases.
Precision RNA Therapies
RNA-based treatments designed to reprogram livers for regeneration outside the body.
Human-Organ Perfusion Models
Proprietary models for testing therapies in live human donor livers.
RNAi Therapeutics for Liver Diseases
Developing novel RNA interference therapies targeting under-treated chronic liver diseases.
Services
Human-first target discovery and validation
Discovery service that generates and integrates human genomic and phenotypic data to identify and validate therapeutic targets using multi-omic analytics and human-system assays.
RNA therapeutic design and lead optimization
Design and chemistry services for RNA-based therapeutics, including progression from target to validated lead using human data-driven workflows.
Data licensing and analytics partnerships
Provision of curated human liver datasets and analytic support under data licence agreements to enable external research on disease drivers and therapeutic hypotheses.
Ex vivo organ perfusion and late-stage validation services
Functional evaluation of candidates using diseased human liver tissue and whole-organ perfusion systems to support late-stage validation and translational assessment.
Human-first target discovery and validation
Discovery service that generates and integrates human genomic and phenotypic data to identify and validate therapeutic targets using multi-omic analytics and human-system assays.
RNA therapeutic design and lead optimization
Design and chemistry services for RNA-based therapeutics, including progression from target to validated lead using human data-driven workflows.
Data licensing and analytics partnerships
Provision of curated human liver datasets and analytic support under data licence agreements to enable external research on disease drivers and therapeutic hypotheses.
Ex vivo organ perfusion and late-stage validation services
Functional evaluation of candidates using diseased human liver tissue and whole-organ perfusion systems to support late-stage validation and translational assessment.
Expertise Areas
- Liver disease therapeutics
- RNA therapeutics development
- Human-first translational research
- Computational biology and machine learning
Key Technologies
- RNA chemistry for therapeutics
- Multi-omics (genomics, transcriptomics)
- Computational biology and machine learning
- Spatial genomics / spatial biology